Serum progesterone concentrations on the day of HCG administration cannot predict pregnancy in assisted reproduction cycles

Reproductive BioMedicine Online

Volumn 8, Issue 2, 2004, Pages 183-190

  Martínez, Francisca ^a   Coroleu, Buenaventura ^a   Clua, Elisabeth ^a   Tur, Rosa ^a   Buxaderas, Rosario ^a   Parera, Nuria ^a   Barri, Pedro N ^a   Balasch, Juan ^b  

^a INSTITUT UNIVERSITARI DEXEUS   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Assisted reproduction; GnRG agonists; Ovarian stimulation; Premature luteinization; Progesterone

Indexed keywords

CHORIONIC GONADOTROPIN; GONADORELIN AGONIST; GONADOTROPIN; HMG LEPORI; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; PROGESTERONE; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL PROTOCOL; CONCEPTION; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; HORMONE RESPONSE; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; PREDICTION; PREGNANCY; PREGNANCY RATE; PROGESTERONE BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; REPRODUCTION; SHORT COURSE THERAPY; SPONTANEOUS ABORTION; STATISTICAL SIGNIFICANCE;

EID: 1042309458     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)60514-7     Document Type: Article

References (32)

1. Balen A 2001 GnRH agonists and superovulation for assisted conception. Infertility and Reproductive Medicine Clinics of North America 12, 89-104.
2. Barri PN, Coroleu B, Marinez F, Veiga A 2000 Stimulation protocols for poor responders and aged women. Molecular and Cellular Endocrinology 166, 15-20.
3. Bomsel-Helmereich O, Huyen LVN, Durand-Gasselin I 1989 Effects of varying doses of HCG on the evolution of preovulatory rabbit follicles and oocytes. Human Reproduction 4, 636-642.
4. Bustillo M, Stern JJ, Coulam CB 1995 Serum progesterone at the time of human chorionic gonadotropin does not predict pregnancy in in-vitro fertilization and embryo transfer. Human Reproduction 10, 2862-2867.
5. Calderón G, Belil L, Arán B et al. 1995 Intracytoplasmic sperm injection versus conventional in-vitro fertilization: first results. Human Reproduction 10, 2835-2839.
6. Copperman AB, Horowitz GM, Kaplan P et al. 1995 Relationship between circulating human chorionic gonadotropin levels and premature luteinization in cycles of controlled ovarian hyperstimulation. Fertility and Sterility 63, 1267-1271.
7. Coroleu B, Carreras O, Veiga A et al. 2000 Embryo transfer under ultrasound guidance improves pregnancy rates after in-vitro fertilization. Human Reproduction 15, 616-620.
8. Dumesic DA 1994 Periovulatory serum progesterone levels as a predictor of pregnancy outcome during ovarian hyperstimulation for assisted reproductive technology. Fertility and Sterility 62, 911-912.
9. Edelstein MC, Seltman HJ, Cox BJ et al. 1990 Progesterone levels on the day of human chorionic gonadotropin administration in cycles with gonadotropin-releasing hormone agonist suppression are not predictive of pregnancy outcome. Fertility and Sterility 54, 853-857.
10. Eldar-Geva T, Margalioth EJ, Brooks B et al. 1998 The origin of serum progesterone during the follicular phase of menotropin-stimulated cycles. Human Reproduction 13, 9-14.
11. Franchin R, de Ziegler D, Taieb J et al. 1993 Premature elevation of plasma progesterone alters pregnancy of in vitro fertilization and embryo transfer. Fertility and Sterility 59, 1090-1094.
12. Filicori M, Flamigni C, Cognini GE et al. 1996 Different gonadotropin and leuprorelin ovulation induction regimens markedly affect follicular fluid hormone levels and folliculogenesis. Fertility and Sterility 65, 387-393.
13. Givens CR, Schriock ED, Dandekar PV, Martin MC 1994 Elevated serum progesterone levels on the day of human chorionic gonadotropin administration do not predict outcome in assisted reproduction cycles. Fertility and Sterility 62, 1011-1017.
14. Hanley JA, McNeil BJ 1982 The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143, 29-36.
15. Harada T, Yoshida S, Katagiri C et al. 1995 Reduced implantation rate associated with a subtle rise in serum progesterone concentration during the follicular phase of cycles stimulated with a combination of a gonadotrophin-releasing hormone agonist and gonadotrophin. Human Reproduction 10, 1060-1064.
16. Hofmann GE, Bergh PA, Guzman I et al. 1993 Premature luteinization is not eliminated by pituitary desensitization with leuprolide acetate in women undergoing gonadotrophin stimulation who demonstrated premature luteinization in a prior gonadotrophin-only cycle. Human Reproduction 8, 695-698.
17. Hofmann GE, Khoury J, Johnson CA et al. 1996 Premature luteinization during controlled ovarian hyperstimulation for in vitro fertilization-embryo transfer has no impact on pregnancy outcome. Fertility and Sterility 66, 980-986.
18. Howles CM, Macnamee MC, Edwards RG et al. 1986 Effect of high tonic levels of luteinising hormone on outcome of in-vitro fertilisation. Lancet 2, 521-522.
19. Legro RS, Ary BA, Paulson RJ et al. 1993 Premature luteinization as detected by elevated serum progesterone is associated with a higher pregnancy rate in donor oocyte in-vitro fertilization. Human Reproduction 8, 1506-1511.
20. Lejeune B, Degueldre M, Camus M et al. 1986 In vitro fertilization and embryo transfer as related to endogenous luteinizing hormone rise or human chorionic gonadotropin administration. Fertility and Sterility 45, 377-383.
21. Lincoln SR, Long CA, Whitworth NS et al. 1995 Elevated luteinizing hormone on the day of human chorionic gonadotropin administration does not reduce cycle fecundity in a low-dose flare-up in vitro fertilization protocol. Fertility and Sterility 63, 563-565.
22. Loumaye E 1990 The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer. Human Reproduction 5, 357-367.
23. Martinez F, Coroleu B, Parera N et al. 2000 Human chorionic gonadotropin and intravaginal natural progesterone are equally effective for luteal phase support in IVF. Gynecological Endocrinology 14, 316-320.
24. Peluso JJ 1990 Role of the amplitude of the gonadotropin surge in the rat. Fertility and Sterility 53, 150-154.
25. Schoolcraft W, Sinton E, Schlenker T et al. 1991 Lower pregnancy rate with premature luteinization during pituitary suppression with leuprolide acetate. Fertility and Sterility 55, 563-566.
26. Serafini P, Stone B, Kerin J et al. 1988 Occurrence of a spontaneous luteinizing hormone surge in superovulated cycles - predictive value of serum progesterone. Fertility and Sterility 49, 86-89.
27. Shulman A, Ghetler Y, Beyth Y, Ben-Nun I 1996 The significance of an early (premature) rise of plasma progesterone in in vitro fertilization cycles induced by a 'long protocol' of gonadotropin releasing hormone analogue and human menopausal gonadotropins. Journal of Assisted Reproduction and Genetics 13, 207-211.
28. Silverberg K, Burns W, Olive D et al. 1990 Serum progesterone levels predict success of in vitro fertilization/embryo transfer in patients stimulated with leuprolide acetate and human menopausal gonadotropins. Journal of Clinical Endocrinology and Metabolism 73, 797-803.
29. Stanger JD, Yovich JL 1985 Reduced in-vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase. British Journal of Obstetrics and Gynecology 92, 85-93.
30. Ubaldi J, Camus M, Smitz J et al. 1996 Premature luteinization in in vitro fertilization cycles using gonadotropin-releasing hormone agonist (GnRH-a) and recombinant follicle-stimulating hormone (FSH) and GnRH-a and urinary FSH. Fertility and Sterility 66, 275-280.
31. Younis JS, Matilsky M, Radin O, Ben-Ami M 2001 Increased progesterone/estradiol ratio in the late follicular phase could be related to low ovarian reserve in in-vitro fertilization-embryo transfer cycles with a long gonadotropin-releasing hormone agonist protocol. Fertility and Sterility 76, 294-299.
32. Zweig MH, Campbell G 1993 Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clinical Chemistry 39, 561-577.